Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamapimod + Pioglitazone in Non-hospitalized COVID-19
2022-500244-37-00Phase 2Completed
- Sponsor
- Curatis
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Pamapimod + Pioglitazone with Placebo (2 arms). Primary endpoint: Number of days alive with minimal symptoms by day 28. Started Aug 2022; status: completed.
02
Drugs
pamapimodpioglitazone
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-500244-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500244-37-00.